Charles River Laboratories International, Inc.
CRLCharles River Laboratories International, Inc. is a global research and development organization specializing in providing essential products and services for the pharmaceutical, biotechnology, and healthcare industries. Founded in 1947, the company offers early-stage contract research, preclinical and clinical support, and laboratory services to assist in the discovery, development, and manufacturing of new drugs and therapies. Its facilities and expertise enable clients to streamline drug development processes and meet regulatory requirements efficiently.
Company News
The global lead optimization services in drug discovery market is projected to grow from USD 4.26 billion in 2024 to USD 10.26 billion by 2034, driven by rising R&D activities, technological advancements, and increasing outsourcing trends in pharmaceutical research.
Charles River Laboratories reported Q3 2025 earnings beating expectations, with revenue of $1.01 billion, but lowered full-year guidance and announced strategic asset sales, causing stock to decline.
Charles River Laboratories reported Q2 2025 earnings with revenue of $1,032.1 million, slightly up 0.6% year-over-year. Non-GAAP EPS was $3.12, beating analyst expectations, but the company faced challenges with organic revenue decline and segment-specific performance issues.
The S&P 500 has faced a turbulent start to 2025, with the index down 8% year-to-date. The two worst-performing stocks, Deckers (DECK) and Charles River Laboratories (CRL), have declined 47% and 42% respectively due to tariffs and regulatory changes. Analysts remain cautiously optimistic on DECK but uncertain about CRL's long-term prospects.
Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.
